This situation is known as “tumor-induced immunosuppression”, characterized by an environment where pro-tumor immune mediators are hierarchized over anti-tumor ones: a Th2 inflammatory response dominance, M2 macrophages, Treg cells, a low capability for antigen presentation and cytotoxicity, and cytokines, such as TGF-β, IL-6, IL-8, IL-10, and VEGF [100]. The gene discussed is TGFB1; the disease is neoplasm.